Aarti Drugs submits Business Responsibility and Sustainability Report for FY25-26
Aarti Drugs submitted its FY25-26 Business Responsibility and Sustainability Report. The report details ESG initiatives, including 10 ZLD facilities, climate change mitigation, and sustainable sourcing. R&D and capex investments for environmental and social impact were 27% and 15% respectively in FY25-26. The company also provides details on corporate governance and stakeholder engagement.
This is a standard regulatory filing of a sustainability report. While important for transparency and ESG tracking, it does not immediately impact the company's financial performance or operational outlook.
The announcement is a routine regulatory filing of the Business Responsibility and Sustainability Report, providing detailed disclosures on ESG practices. It does not contain new financial performance data or significant strategic changes that would warrant a positive or negative sentiment.
Aarti Drugs Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, in compliance with Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This report, which details the company's environmental, social, and governance initiatives and performance, is available on the company's website along with the Annual Report and the Notice of the 41st Annual General Meeting.
The BRSR report covers a wide array of disclosures, including corporate identity, business activities, operational details, employee statistics, and CSR activities. It highlights the company's commitment to sustainable sourcing, energy efficiency, waste management, and occupational health and safety. Aarti Drugs emphasizes its efforts in climate change mitigation, sustainable supply chain management, and water conservation, with 10 out of 12 API manufacturing facilities operating on a Zero Liquid Discharge (ZLD) basis.
The report also details the company's policies on anti-corruption, conflict of interest, and data privacy, alongside performance against its ESG goals. Aarti Drugs has invested significantly in R&D and capital expenditure aimed at improving environmental and social impacts, with 27% of R&D and 15% of capex investments focused on these areas for FY25-26. The company also reports on its stakeholder engagement, including grievance redressal mechanisms and training programs for employees and value chain partners on responsible business practices.
A plain-language summary of a public exchange filing by Aarti Drugs Limited. Read the original for the full detail.